Dermira Elects Halley E. Gilbert to its Board of Directors
November 13 2019 - 4:05PM
Business Wire
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company
dedicated to bringing biotech ingenuity to medical dermatology by
delivering differentiated, new therapies to the millions of
patients living with chronic skin conditions, today announced the
election of Halley E. Gilbert to its board of directors.
“We are excited to welcome Halley Gilbert to Dermira’s board of
directors,” said Tom Wiggans, chairman and chief executive officer
of Dermira. “Dermira will benefit from Halley’s breadth of
experience in building successful commercial biotechnology
companies.”
Ms. Gilbert currently serves as senior vice president, corporate
development and chief administrative officer of Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) overseeing corporate and
business development, legal, compliance and government affairs. Ms.
Gilbert has more than two decades of experience guiding
biopharmaceutical companies through transformational change, as
well as expertise in corporate transactions, governance and the
operational and strategic issues relevant to launching new
medicines. Prior to joining Ironwood, Ms. Gilbert was vice
president, deputy general counsel at Cubist Pharmaceuticals, Inc.,
where she supported the launch of Cubist’s first acute care
antibiotic, and prior to Cubist, she served as corporate counsel at
Genzyme Corp. She began her career at Skadden, Arps, Slate, Meagher
& Flom LLP, where she specialized in mergers and acquisitions
and securities law. Ms. Gilbert holds a J.D. from Northwestern
University School of Law and a B.A. from Tufts University.
“I am excited to join the Dermira board at a time when the
company continues to demonstrate its ability to successfully
commercialize its first therapy and develop what might one day
represent a best-in-disease therapy for a chronic and debilitating
skin disease,” said Halley Gilbert. “I look forward to sharing my
experience to maximize opportunities and support the company’s
mission to help patients living with chronic skin conditions.”
About Dermira
Dermira is a biopharmaceutical company dedicated to bringing
biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of patients living
with chronic skin conditions. Dermira is committed to understanding
the needs of both patients and physicians and using its insight to
identify, develop and commercialize leading-edge medical
dermatology products. The company’s approved treatment, QBREXZA®
(glycopyrronium) cloth, is indicated for pediatric and adult
patients (ages 9 and older) with primary axillary hyperhidrosis
(excessive underarm sweating). Please see the QBREXZA prescribing
information. Dermira is evaluating lebrikizumab in a Phase 3
clinical development program for the treatment of
moderate-to-severe atopic dermatitis (a severe form of eczema) and
has early-stage research and development programs in other areas of
dermatology. Dermira is headquartered in Menlo Park, Calif. For
more information, please visit http://www.dermira.com. Follow
Dermira on Twitter, LinkedIn and Instagram.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website (www.dermira.com), LinkedIn page
(https://www.linkedin.com/company/dermira-inc-), corporate
Instagram account (https://www.instagram.com/dermira_inc/) and
corporate Twitter account (@DermiraInc) as channels of distribution
of information about its company, product candidates, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Dermira may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Dermira’s website, LinkedIn
page, Instagram and Twitter accounts in addition to following its
SEC filings, news releases, public conference calls and
webcasts.
Forward-Looking Statements
The information in this news release contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the “safe harbor” created by those sections. This news release
contains forward-looking statements that involve substantial risks
and uncertainties, including statements with respect to Dermira’s
goal of bringing biotech ingenuity to medical dermatology by
delivering differentiated, new therapies to the millions of
patients living with chronic skin conditions and Dermira’s ability
to continue to successfully commercialize its first therapy and
develop what might one day represent a best-in-disease therapy for
a chronic and debilitating skin disease. These statements deal with
future events and involve known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. Factors
that could cause actual results to differ materially include risks
and uncertainties such as those relating to the design,
implementation and outcomes of Dermira’s clinical trials; the
impact of competitive clinical trials, products and therapies;
Dermira’s dependence on third-party clinical research
organizations, manufacturers, suppliers and distributors; the
outcomes of future meetings with regulatory agencies; market
acceptance of Dermira’s current and potential products; Dermira’s
ability to attract and retain key employees; Dermira’s ability to
manage the growth and complexity of its organization; Dermira’s
ability to maintain, protect and enhance its intellectual property;
and Dermira’s ability to continue to stay in compliance with its
material contractual obligations, applicable laws and regulations.
You should refer to the section entitled “Risk Factors” set forth
in Dermira’s Annual Report on Form 10-K, Dermira’s Quarterly
Reports on Form 10-Q and other filings Dermira makes with the SEC
from time to time for a discussion of important factors that may
cause actual results to differ materially from those expressed or
implied by Dermira’s forward-looking statements. Furthermore, such
forward-looking statements speak only as of the date of this news
release. Dermira undertakes no obligation to publicly update any
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191113005839/en/
Media: Erica Jefferson Vice President, Corporate Communications
650-421-7216 media@dermira.com
Investors: Andrew Guggenhime Chief Financial Officer
650-421-7200 investor@dermira.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Sep 2023 to Sep 2024